Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024

Rhea-AI Summary

Cytokinetics, Incorporated (Nasdaq: CYTK) will present the Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy at CMR 2024 in London, UK from January 25-27, 2024. The presentation will be conducted by Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University, during the Rapid Fire session on January 25, 2024, at 2:55 – 3:00 PM GMT.

SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January 25-27, 2024.

Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: January 25, 2024
Session Title: Rapid Fire – Large Clinical Trials and Registries
Session Time: 2:40 – 3:40 PM GMT
Presentation Time: 2:55 – 3:00 PM GMT
Location: Kiosk 6R-TC-04, Cambridge

About Cytokinetics

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory interactions for aficamten, its next-in-class cardiac myosin inhibitor, following positive topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in two ongoing Phase 3 clinical trials: MAPLE-HCM, evaluating aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM and ACACIA-HCM, evaluating aficamten in patients with non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility, and CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757

FAQ

What is the title of the upcoming presentation at CMR 2024?

The title of the upcoming presentation at CMR 2024 is 'Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study'.

Who will be the presenter at the CMR 2024 presentation?

The presenter at the CMR 2024 presentation will be Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University.

When and where will the CMR 2024 presentation take place?

The CMR 2024 presentation will take place online and in person in London, UK from January 25-27, 2024. The specific presentation time will be on January 25, 2024, at 2:55 – 3:00 PM GMT, at Kiosk 6R-TC-04, Cambridge.